Literature DB >> 30342839

Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.

Michaela E Johnson1, Benjamin Stecher2, Viviane Labrie3, Lena Brundin3, Patrik Brundin4.   

Abstract

We hypothesize that Parkinson's disease (PD) pathogenesis can be divided into three temporal phases. During the first phase, 'triggers', such as viral infections or environmental toxins, spark the disease process in the brain and/or peripheral tissues. Triggers alone, however, may be insufficient, requiring 'facilitators' like peripheral inflammation for PD pathology to develop. Once the disease manifests, 'aggravators' spur further neurodegeneration and exacerbate symptoms. Aggravators are proposed to include impaired autophagy and cell-to-cell propagation of α-synuclein pathology. We believe clinical trials need to consider these three phases and target potential therapies at the appropriate stage of the disease process in order to be effective.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Parkinson’s disease; clinical trials; genetics; inflammation; α-synuclein

Mesh:

Substances:

Year:  2018        PMID: 30342839      PMCID: PMC6623978          DOI: 10.1016/j.tins.2018.09.007

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  77 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 2.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

3.  Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.

Authors:  Walter Maetzler; Daniela Berg; Natalie Schalamberidze; Arthur Melms; Klaus Schott; Jakob C Mueller; Lucy Liaw; Thomas Gasser; Cordula Nitsch
Journal:  Neurobiol Dis       Date:  2006-12-26       Impact factor: 5.996

Review 4.  Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.

Authors:  David Sulzer
Journal:  Trends Neurosci       Date:  2007-04-05       Impact factor: 13.837

Review 5.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Trends Immunol       Date:  2008-07-01       Impact factor: 16.687

Review 6.  Immune responses to the microbiota at the intestinal mucosal surface.

Authors:  Breck A Duerkop; Shipra Vaishnava; Lora V Hooper
Journal:  Immunity       Date:  2009-09-18       Impact factor: 31.745

7.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.

Authors:  V N Uversky; J Li; A L Fink
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

8.  Parkinsonian signs and substantia nigra neuron density in decendents elders without PD.

Authors:  G Webster Ross; Helen Petrovitch; Robert D Abbott; James Nelson; William Markesbery; Daron Davis; John Hardman; Lenore Launer; Kamal Masaki; Caroline M Tanner; Lon R White
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

9.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

10.  Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.

Authors:  Hui-Ming Gao; Paul T Kotzbauer; Kunihiro Uryu; Susan Leight; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2008-07-23       Impact factor: 6.167

View more
  85 in total

1.  Diesel exhaust exposure alters the expression of networks implicated in neurodegeneration in zebrafish brains.

Authors:  M Saeid Jami; Hiromi Murata; Lisa M Barnhill; Sharon Li; Jeff M Bronstein
Journal:  Cell Biol Toxicol       Date:  2021-05-31       Impact factor: 6.691

Review 2.  Can infections trigger alpha-synucleinopathies?

Authors:  Christopher T Tulisiak; Gabriela Mercado; Wouter Peelaerts; Lena Brundin; Patrik Brundin
Journal:  Prog Mol Biol Transl Sci       Date:  2019-07-03       Impact factor: 3.622

3.  Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Authors:  Jason Candreva; Edward Chau; Margaret E Rice; Jin Ryoun Kim
Journal:  Biochemistry       Date:  2019-12-30       Impact factor: 3.162

4.  G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.

Authors:  Nicolas Arbez; XiaoFei He; Yong Huang; Mark Ren; Yideng Liang; Frederick C Nucifora; Xiaofang Wang; Zhong Pei; Lino Tessarolo; Wanli W Smith; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

Review 5.  Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2020-01-28       Impact factor: 3.575

Review 6.  Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.

Authors:  David K Simon; Caroline M Tanner; Patrik Brundin
Journal:  Clin Geriatr Med       Date:  2019-08-24       Impact factor: 3.076

Review 7.  Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Authors:  Malvyne Rolli-Derkinderen; Laurène Leclair-Visonneau; Arnaud Bourreille; Emmanuel Coron; Michel Neunlist; Pascal Derkinderen
Journal:  J Neurol       Date:  2019-04-12       Impact factor: 4.849

Review 8.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

9.  Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson's disease.

Authors:  Joohyung Lee; Paulo Pinares-Garcia; Hannah Loke; Seungmin Ham; Eric Vilain; Vincent R Harley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

Review 10.  The Microbiome as a Modifier of Neurodegenerative Disease Risk.

Authors:  P Fang; S A Kazmi; K G Jameson; E Y Hsiao
Journal:  Cell Host Microbe       Date:  2020-08-12       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.